Into A Post-COVID World: Overcoming Pharmaceutical Supply Chain Challenges And Unlocking CDMO Opportunities

The supply chain disruptions brought on by COVID-19 opened up new opportunities for CDMOs to do something new - collaborate with each other. CDMOs partnered with pharma companies and other CDMOs to bring their best scientists together in an effort to solve a global problem that had never been seen before. By combining their shared expertise and resources, they have succeeded in delivering medicines to patients faster than ever before.

The industry has been plagued by supply chain disruptions over the last two years, and capacity constraints for pharmaceutical development are expected to continue for a number of reasons. The high number of new drug products to treat COVID-19 receiving fast approval and the build-up in demand from clinical trials for drugs that were delayed during the pandemic, combined with current talent shortages in the market, are significantly impacting the supply chain.

Learn how this evolving manufacturing landscape can accelerate development timelines and help various partners across the supply chain overcome continuing capacity restraints for pharmaceutical development.